Management of febrile neutropaenia: ESMO Clinical Practice Guidelines.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Annals of Oncology

• Publication date

  2010-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/ANNONC/MDW325PMID 27664247
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review

  2016cited by this paper
• Third generation cephalosporin resistant Enterobacteriaceae and multidrug resistant gram-negative bacteria causing bacteremia in febrile neutropenia adult cancer patients in Lebanon, broad spectrum antibiotics use as a major risk factor, and correlation with poor prognosis

  2015cited by this paper
• Combination Antifungal Therapy for Invasive Aspergillosis

  2015cited by this paper
• Outpatient management of febrile neutropenia associated with cancer chemotherapy: risk stratification and treatment review.

  2015cited by this paper
• Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)

  2014cited by this paper
• The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials

  2014cited by this paper
• The current spectrum of infection in cancer patients with chemotherapy related neutropenia

  2014cited by this paper
• Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients.

  2013cited by this paper
• Oral antibiotics for fever in low-risk neutropenic patients with cancer: a double-blind, randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin/clavulanic acid combination therapy--EORTC infectious diseases group trial XV.

  2013cited by this paper
• Recent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance

  2013cited by this paper
• Patients at High Risk of Invasive Fungal Infections

  2012cited by this paper
• 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.

  2011cited by this paper
• Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis

  2011cited by this paper
• Febrile mucositis in haematopoietic SCT recipients

  2009cited by this paper
• Optimization of the detection of microbes in blood from immunocompromised patients with haematological malignancies.

  2009cited by this paper
• Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer.

  2009cited by this paper
• Management of the catheter in documented catheter-related coagulase-negative staphylococcal bacteremia: remove or retain?

  2009cited by this paper
• Evolving health effects of Pneumocystis: one hundred years of progress in diagnosis and treatment.

  2009cited by this paper
• Central venous catheter-related infections in hematology and oncology

  2008cited by this paper
• Bloodstream infections in cancer patients with febrile neutropenia.

  2008cited by this paper
• Neutropenic fever and severe sepsis in adult acute myeloid leukemia (AML) patients receiving intensive chemotherapy: Causes and consequences

  2008cited by this paper
• Salvage therapy for invasive aspergillosis.

  2008cited by this paper
• Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice

  2008cited by this paper
• Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia.

  2008cited by this paper
• Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients.

  2008cited by this paper
• Clinical practice of obtaining blood cultures from patients with a central venous catheter in place: an international survey.

  2008cited by this paper
• Bacteraemia in febrile neutropenic cancer patients.

  2007cited by this paper
• Meta-analysis: Effect of Prophylactic Hematopoietic Colony-Stimulating Factors on Mortality and Outcomes of Infection

  2007cited by this paper
• Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review.

  2007cited by this paper
• Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial).

  2007cited by this paper
• Outpatient therapy for febrile neutropenia

  2007cited by this paper
• Management of sepsis in neutropenia: guidelines of the infectious diseases working party (AGIHO) of the German Society of Hematology and Oncology (DGHO)

  2006cited by this paper
• Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials

  2006cited by this paper
• Comment on: empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials.

  2006cited by this paper
• 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

  2006cited by this paper
• Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials.

  2005cited by this paper
• A survey of the antibiotic treatment of febrile neutropenia in haematology units in the United Kingdom.

  2005cited by this paper
• Meta-Analysis: Antibiotic Prophylaxis Reduces Mortality in Neutropenic Patients

  2005cited by this paper
• Bacterial infections in low‐risk, febrile neutropenic patients

  2005cited by this paper
• Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas.

  2005cited by this paper
• Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients: a systematic review and meta-analysis of randomized trials.

  2004cited by this paper
• Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.

  2004cited by this paper
• Outcomes of Hickman Catheter Salvage in Febrile Neutropenic Cancer Patients With Staphylococcus aureus Bacteremia

  2003cited by this paper
• Bloodstream Infection in Neutropenic Cancer Patients Related to Short-Term Nontunnelled Catheters Determined by Quantitative Blood Cultures, Differential Time to Positivity, and Molecular Epidemiological Typing with Pulsed-Field Gel Electrophoresis

  2003cited by this paper
• Greater risks of chemotherapy toxicity in elderly patients with cancer.

  2003cited by this paper
• Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study

  2003cited by this paper
• Central venous catheter removal versus in situ treatment in neonates with coagulase-negative staphylococcal bacteremia.

  2002cited by this paper
• Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.

  2002cited by this paper
• Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a meta-analysis.

  2002cited by this paper
• Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients.

  2001influential reference
• The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients.

  2000cited by this paper
• Pathogen 'shift' in febrile neutropenia.

  1999cited by this paper
• A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy.

  1999cited by this paper
• A randomised comparison of meropenem with cefotaxime or ceftriaxone for the treatment of bacterial meningitis in adults. Meropenem Meningitis Study Group.

  1995cited by this paper

• Effectiveness and safety of pegylated filgrastim (Pelgraz®) for the prevention of febrile neutropenia during cancer chemotherapy in all-day practice in Germany

  2026cites this paper
• Early Discontinuation of Empiric Antibiotic Therapy in Children with Cancer and Febrile Neutropenia: A Narrative Review

  2026cites this paper
• Cancer Treatment Beyond the Tumor: Physiological Reserve, Therapeutic Tolerance, and Durable Disease Control

  2026cites this paper
• Prevention and management of febrile neutropenia in acute myeloid leukaemia and higher risk myelodysplastic syndrome: An international survey of current practice.

  2026cites this paper
• Lymphomas During Pregnancy: Diagnostic and Therapeutic Challenges

  2026cites this paper
• Evidence-based AGIHO guideline update on prophylaxis of infectious complications with granulocyte-stimulating factors (G-CSF) for the treatment of adult patients with cancer.

  2026cites this paper
• Assessment of bacterial infection risk factors and related complications in newly diagnosed multiple myeloma: A retrospective cohort analysis.

  2026cites this paper
• Population Pharmacokinetics and Model-Informed Dose Optimization of Teicoplanin in Adults with Hematological Malignancies

  2026cites this paper
• Efficacy of dual HER2 blockade in neoadjuvant HER2-positive breast cancer: a meta-analysis of RCTs

  2026cites this paper
• Teaching cancer patients undergoing chemotherapy in the National Health Service to use daily self-moxibustion to reduce chemotherapy-induced pancytopenia: a feasibility study

  2026cites this paper
• Microbiologic Profile, Antimicrobial Resistance patterns, and Outcomes in Febrile Neutropenia in Eastern India: A Retrospective Analysis

  2026cites this paper
• Factors Influencing the Use of G-CSF in Drug-Induced Agranulocytosis.

  2026cites this paper
• Evaluation of Direct Medical Costs Associated With High-Risk Febrile Neutropenia Among Cancer Patients in a Tertiary Care Center.

  2026cites this paper
• Management of adverse events associated with TROP2-targeted antibody-drug conjugates in cancer patients.

  2026cites this paper
• Clinical utility of immature granulocyte monitoring for optimizing g-CSF use during chemotherapy-induced neutropenia.

  2026cites this paper
• Critical care in hematopoietic stem cell transplantation: Common complications and management

  2026cites this paper
• Impact of Manchester Triage on the Referral Pathway of Febrile Neutropenia Patients in the Emergency Department – A Single-Center Experience

  2026cites this paper
• G-CSF biosimilars vs. originator filgrastim for febrile neutropenia prophylaxis: systematic review of cost-effectiveness, safety, and clinical outcomes

  2026cites this paper
• Consensus guidelines for the subsequent management of neutropenic fever after empiric therapy

  2025cites this paper
• Risk of Potentially Neurotoxic Exposure in Infants Under High-Dose Cefepime Treatment—A Pharmacometric Simulation Study

  2025cites this paper
• Consensus guidelines for patient and carer education on neutropenic fever

  2025cites this paper
• Simulation-Based Assessment of Empirical Amikacin Dosing in High-Risk Adults With Febrile Neutropenia and Hematological Malignancies Using Population Pharmacokinetic Modeling.

  2025cites this paper
• The impact of fluoroquinolone-resistant enterobacterales colonization on fluoroquinolone prophylaxis efficacy in hematopoietic cell transplant recipients

  2025cites this paper
• A Prospective Observational Study for Assessment of Chemotherapy-Induced Adverse Drug Reactions in Cancer Patients

  2025cites this paper
• Impact of lymphopenia and hypogammaglobulinemia on outcomes in neutropenic patients with hematological malignancies.

  2025cites this paper
• Febrile Neutropenia in the Context of Clozapine-Induced Agranulocytosis (CIA) and Myelodysplastic Syndrome: Importance of a Multidisciplinary Approach

  2025influential citation
• The role of antibacterial prophylaxis in high-risk neutropenia: benefits, risks, and current perspectives.

  2025cites this paper
• Long-Term Oncological Outcomes of Granulocyte Colony-Stimulating Factor (G-CSF) Treatment in Gastrointestinal Cancers: A Systematic Review and Meta-Analysis

  2025cites this paper
• The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studies.

  2025cites this paper
• Consensus guidelines for antibacterial prophylaxis in patients with neutropenia

  2025cites this paper
• The latest updates on the proper use of fluoroquinolones - Actualisation 2025 update by the SPILF and the GPIP.

  2025cites this paper
• Grade 3 and 4 Chemotherapy-Induced Neutropenia in Patients Followed at a Referral Hospital in Cameroon

  2025cites this paper
• A Three-Year Retrospective Analysis of the Common Isolated Microorganisms and the Sensitivity Pattern of Blood Culture in Children with Cancer

  2025cites this paper
• The Role of Initial Neutropenia and Neutrophil Dynamics in Personalizing Chemotherapy for Platinum-Resistant Ovarian Cancer

  2025cites this paper
• Severe agranulocytosis during prolonged trimethoprim-sulfamethoxazole therapy in an elderly male: a case report with causality assessment and literature review

  2025cites this paper
• Microbiological profile and 30-day mortality outcomes in febrile neutropenia among solid malignancy patients: a multicentre retrospective study from resource-limited setting

  2025cites this paper
• Optimizing nursing care for neutropenic patients: a holistic perspective on education, support, and clinical management

  2025cites this paper
• Emergency department evaluation of early warning scores in predicting mortality in febrile neutropenia patients.

  2025cites this paper
• Risks of haematological malignancies in patients treated for solid tumours associated with the use of pegylated granulocyte colony-stimulating factors: A single centre study since 2005

  2025cites this paper
• The use of granulocyte colony-stimulating factors in the management of breast cancer patients

  2025cites this paper
• Continuous temperature monitoring for the detection of fever in haemato‐oncology patients: a pilot study of two wearable devices (THERMAL)

  2025cites this paper
• Rethinking immunotherapy in patients with SCLC with poor performance status.

  2025cites this paper
• Low rate of infectious mortality omitting fluoroquinolone prophylaxis in high-risk hematological patients, a single centre experience

  2025cites this paper
• Therapiemanagement des mCRPC bei Kombinationen mit PARP-Inhibitoren in der klinischen Praxis

  2025cites this paper
• Can febrile neutropenia re-invent its self?

  2025cites this paper
• Assessing the role of bronchoscopy in the management of patients with acute leukemia—a transversal study and proposal of evaluation

  2025cites this paper
• Economic Burden of Intravenous Decitabine Administration in Patients Affected by Acute Myeloid Leukemia Ineligible for Induction Chemotherapy and Impact of Oral Formulation Introduction: A Micro-Costing Study in Italy

  2025cites this paper
• Effect of Prophylactic Dual Histamine Blockade on Filgrastim-Induced Bone Pain in Female Cancer Patients: Single Institutional Analysis

  2025cites this paper
• A Population‐Based Study of Infectious Diseases Mortality Risk in Patients With Hematologic Malignancies 2000–2020

  2025cites this paper
• Is it appropriate to select patients for primary prophylactic use of pegfilgrastim based on the risk of febrile neutropenia?

  2025cites this paper
• Sacituzumab Govitecan in the Treatment of Triple-Negative Breast Cancer: Present and Future

  2025cites this paper
• Neutropenic events associated with new anticancer treatments, from pathophysiology to practice: a scoping review—NEW Group (Neutropenic Events Working Group)

  2025cites this paper
• Hematological emergencies in intensive care unit: Recognition, management protocols, and multidisciplinary care

  2025cites this paper
• Glucocorticoids rarely required in granulocyte colony-stimulating factor-associated large-vessel vasculitis: Japanese cancer centre cohort.

  2025cites this paper
• Telpegfilgrastim for the prophylaxis of chemotherapy-induced neutropenia in patients with high- or medium-risk non-myeloid malignancies: a multicenter, retrospective study

  2025influential citation
• Early Carbapenem De-escalation for Patients With High-Risk Febrile Neutropenia and Hematologic Malignancy

  2025cites this paper
• Effectiveness and Safety of Sacituzumab Govitecan in Real-World Clinical Practice in Patients with Metastatic Triple-Negative and HR+/HER2-Negative Breast Cancer

  2025cites this paper
• Global variation in antibiotic prescribing guidelines and the implications for decreasing AMR in the future

  2025cites this paper
• Efficacy and Safety of mDCF as First-Line Therapy for HER2-Negative Advanced Gastric Cancer in Vietnam: A Real-World Retrospective Study

  2025cites this paper
• Consensus guidelines for ambulatory care for neutropenic fever

  2025cites this paper
• [Management of febrile neutropenia].

  2025cites this paper
• Impact of single dose of pegfilgrastim on peripheral blood stem cell harvest in patients with multiple myeloma or malignant lymphoma

  2025cites this paper
• Outcomes and microbiological patterns of bacteremia in chemotherapy-related febrile neutropenia at a tertiary facility in Kenya

  2025influential citation
• Limited Diagnostic and Therapeutic Value of Chest X-Rays in Hematological Patients With Febrile Neutropenia

  2025cites this paper
• REaCT-5G: a randomized trial of bone pain with 5-day filgrastim vs pegfilgrastim for neutropenia in breast cancer

  2025cites this paper
• Development of a predictive model for neutropenia risk in Japanese breast cancer patients treated with doxorubicin and cyclophosphamide

  2025cites this paper
• Case report of an adult with rhabdomyosarcoma of lung with ovarian metastases or the other way around: Do's and don'ts with review of literature.

  2025cites this paper
• Febrile neutropenia

  2025cites this paper
• Factors influencing hospital length of stay in febrile neutropenia: A retrospective cohort study of Turkish patients with solid tumors

  2025cites this paper
• The efficacy and safety of ripertamab in the treatment of idiopathic membranous nephropathy: a retrospective multicenter cohort study

  2025cites this paper
• Microbial Crosstalk with Therapy: Pharmacomicrobiomics in AML—One Step Closer to Personalized Medicine

  2025cites this paper
• Mortality Risk of Colistin vs. Non-Colistin Use in Cancer Patients with Multidrug-Resistant Gram-Negative Bacterial Infections: Stratified by Resistance Profile and Concomitant Medications

  2025cites this paper
• Prognostic Factors for 28-Day Mortality in Pediatric Patients with Acute Leukemia and Candidemia Following Intensive Chemotherapy: A Retrospective Study

  2025influential citation
• Culture-positive mould infections in patients with haemato-oncological diseases

  2025cites this paper
• Validation of an algorithm for identifying patients with febrile neutropenia: an epidemiological study using real-world data in Japan

  2025influential citation
• "I Feel Like My Child's Health Is Hanging by a Thread": A Grounded Theory of Experiences of Parents of Children With Cancer During Emergency Department Visits.

  2025cites this paper
• Identifying Leukopenia, Renal Dysfunction and Other Factors Limiting Concomitant Chemoradiotherapy in Locally Advanced Cervical Cancer: A Way to Focus on the Importance of Supportive Care and Potentially Improve Treatment Results?

  2025cites this paper
• Bacterial agents and antibiotic resistance in febrile neutropaenia in Africa: A systematic review and meta-analysis

  2025cites this paper
• Evaluation of the effects of regulatory T cells on survival outcomes in patients with acute leukemia who developed febrile neutropenia

  2025cites this paper
• Distribution of Oncological Diagnoses in Pediatric Patients With Febrile Neutropenia and Sepsis: Is There an Association?

  2025cites this paper
• Modeling the Impact of Antimicrobial Resistance on Medical Preparedness and Response for a Nuclear or Radiological Public Health Emergency

  2025cites this paper
• Practice of inflammatory biomarkers for prediction of infectious complications after autologous hematopoietic stem cell transplantation

  2025cites this paper
• Efficacy and safety of pegylated recombinant human granulocyte colony-stimulating factor as a support for chemotherapy for gestational trophoblastic neoplasia: a propensity score matching analysis

  2025cites this paper
• Interpretable machine learning model to predict 90-day radiographically confirmed pneumonia after chemotherapy initiation in non-Hodgkin lymphoma: development and internal validation of a single-center cohort

  2025cites this paper
• Predictive Performance of Neutrophil Parameter for Neutrophil Recovery From Prolonged Neutropenia

  2025influential citation
• Mortality and Treatment Outcomes in Pediatric Malignancy Patients with Invasive Cutaneous Fungal Infections: Evaluating the Impact of Combination Therapy and Surgical Debridement, Experience from Referral Oncology Teaching Hospital

  2025cites this paper
• Contribution of paranasal sinus, chest, and abdomen/pelvis computed tomography in patients with febrile neutropenia

  2025influential citation
• PCT-to-albumin ratio and CRP-to-albumin ratio as predictors of febrile neutropenia complications: a prospective observational trial

  2025cites this paper
• A Reappraisal of Carbapenems Dosing in Febrile Neutropenic Patients.

  2025cites this paper
• Effectiveness and safety of the Fuzheng Buxue recipe for myelosuppression induced by platinum-based chemotherapy: a quasi-experimental clinical trial

  2025cites this paper
• Improving UTI Diagnostics in Oncology: Reliability of Reflex Urine Culture in Immunosuppressed Neutropenic and Non-neutropenic Cancer Patients.

  2025cites this paper
• Pooled safety analysis of two phase 3 studies investigating trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer

  2025cites this paper
• Granulocyte colony‐stimulating factor‐associated aortitis in a man with advanced prostate cancer

  2025cites this paper
• Secondary Neutropenias

  2025cites this paper
• Managing adverse events in patients with metastatic colorectal cancer receiving trifluridine/tipiracil in combination with bevacizumab

  2025cites this paper
• Febril Nötropenide Tiyol/Disülfid Homeostazı ve Kanserde Destekleyici Bakım için Çok Uluslu Derneği Risk Skoru

  2025cites this paper
• Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial

  2025cites this paper
• The Optimal Timing and Duration of Daily G‐CSF for the Primary Prevention of Febrile Neutropenia in Breast Cancer Patients Undergoing Adjuvant TAC Chemotherapy

  2025cites this paper
• Febrile neutropenia management in high-risk neutropenic patients: a narrative review on antibiotic prophylaxis and empirical treatment

  2025cites this paper
• Cause and effect? A review of the impact of antibiotics on the gut microbiome in patients undergoing hematopoietic stem cell transplantation

  2025influential citation